Recent developments for NuCana plc include corporate actions to improve capital structure and liquidity, clinical data presentations, and management changes.

• NuCana plc completed cancellation of all remaining Series A warrants following a successful capital raise in July 2025 [N1].
• The company announced a change in its ADS ratio to enhance liquidity and comply with Nasdaq requirements in July 2025 [N2].
• NuCana announced an expansion study of NUC-7738 in combination with pembrolizumab for PD-1 inhibitor-resistant melanoma in June 2025 [N3].
• Initial data from a Phase 1b/2 modular study of NUC-3373 was announced in November 2024 [N6].
• The company presented clinical data on synergistic effects of NUC-7738 and PD-1 inhibition in renal cell carcinoma organoids at the ESMO Congress 2025 [S2].
• Management changes include the appointment of Theresa Bruce as Chief Operating Officer in January 2026 [S2].
• CEO Hugh Griffith returned to his role in December 2025 after a leave of absence [S2].

NuCana's clinical programs, particularly the expansion study of NUC-7738 combined with pembrolizumab, demonstrate active pipeline development in oncology. Positive initial data from Phase 1b/2 studies of NUC-3373 and presentations at major oncology congresses indicate progress in clinical validation. The company's strong liquidity position supports ongoing operations and development activities. Management continuity and recent capital structure improvements may enhance operational stability and market compliance.

NuCana reported a net loss of £29.35 million GBP for 2025, reflecting the high costs typical of clinical-stage biopharmaceutical companies without commercial products. The absence of disclosed revenues and reliance on capital raises pose financial sustainability risks. Clinical development outcomes remain uncertain, and regulatory hurdles may delay or prevent product approvals. Market liquidity and share price volatility could be impacted by the company's ongoing need for financing and clinical trial results.

NuCana's moat is primarily based on its proprietary drug candidates, including NUC-7738 and NUC-3373, supported by issued patents such as the composition of matter patent granted in China. The company's clinical-stage status and ongoing trials in oncology, particularly in PD-1 inhibitor-resistant melanoma, position it within a specialized niche. The management team's extensive experience and the company's intellectual property portfolio contribute to its competitive positioning. However, as a clinical-stage company without commercial products, its moat is contingent on successful clinical development and regulatory approvals.

• Clinical Development Risk: As a clinical-stage biopharmaceutical company, NuCana faces risks related to the successful completion of clinical trials, regulatory approvals, and eventual commercialization of its drug candidates.
• Financial Sustainability Risk: The company reported a net loss and relies on capital raises to fund operations, which may dilute shareholders and impact financial stability if future funding is not secured.
• Market and Liquidity Risk: Changes in ADS ratio and warrant cancellations indicate efforts to improve liquidity, but market volatility and compliance with Nasdaq requirements remain risks.

• NuCana plc is a clinical-stage biopharmaceutical company headquartered in Edinburgh, United Kingdom.
• The company focuses on oncology drug development, including clinical programs for NUC-7738 and NUC-3373.
• NUC-7738 is being studied in combination with pembrolizumab for PD-1 inhibitor-resistant melanoma, with expansion studies ongoing.
• The company announced initial data from a Phase 1b/2 modular study of NUC-3373.
• NuCana completed cancellation of all remaining Series A warrants following a successful capital raise in July 2025.
• The company changed its ADS ratio to enhance liquidity and comply with Nasdaq requirements in July 2025.
• Management includes CEO Hugh Griffith (co-founder, returned to CEO role December 2025), Chief Medical Officer Jeffrey Bloss, Head of Translational Medicine David Harrison, Interim CFO Ian Webster, and COO Theresa Bruce (appointed January 2026).
• The board includes experienced non-executive directors with backgrounds in biotech and pharmaceuticals.
• Financial snapshot as of December 31, 2025: cash and equivalents of £24.25 million GBP, current assets of £26.86 million GBP, current liabilities of £4.79 million GBP, resulting in a current ratio of 5.6 and cash ratio of 5.06, indicating strong liquidity.
• The company reported a net loss of £29.35 million GBP for the year ended December 31, 2025, with basic and diluted EPS of zero.
• The company has granted significant share options and long-term incentive plan awards to executives and directors.
• Recent clinical data presentations include synergistic effects of NUC-7738 with PD-1 inhibition in renal cell carcinoma organoids and melanoma patient data at ESMO congresses in 2025.
• The company holds patents covering NUC-7738's composition of matter, including a patent issued by the China National Intellectual Property Administration in 2025.